Seminars in Hematology
Volume 40, Issue 1 , Pages 13-21 , January 2003

Prognostic factors in chronic myeloid leukemia: Allografting

References 

  1. Barrett AJ, Ringden O, Zhang M-J, et al.  Effect of nucleated cell dose on relapse and survival in identical twin transplants for leukemia. Blood. 2000;95:3323–3327
  2. Beelen DW, Graeven U, Elmaagacli AH, et al.  Prolonged administration of interferon alpha in patients with chronic phase Philadelphia positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood. 1995;85:1990–2981
  3. Bornhauser M, Kiehl M, Siegert W, et al.  Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: A retrospective analysis. Br J Haematol. 2001;115:119–124
  4. Bostrom L, Ringden O, Gratama JW, et al.  A role of herpes virus serology for the development of acute GvHD. Bone Marrow Transplant. 1990;5:321–326
  5. Champlin RE, Schmitz N, Horowitz MM, et al.  Blood stem cells versus bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood. 2000;95:3702–3709
  6. Clift R, Goldman J, Gratwohl A, et al.  Proposals for standardized reporting of results of bone marrow transplantation for leukaemia. Bone Marrow Transplant. 1989;4:445–448
  7. Clift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by marrow transplantation. Blood. 1993;82:1954–1956
  8. Craddock C, Szydlo RM, Klein JP, et al.  Estimating leukemia-free survival after allografting for chronic myeloid leukemia: A new method that takes into account patients who relapse and are restored to complete remission. Blood. 2000;96:86–90
  9. Druker BJ, Talpaz M, Resta DJ, et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–1037
  10. Flowers ME, Parker PM, Johnston LJ, et al.  Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: Long-term follow-up of a randomized trial. Blood. 2002;15:415–419
  11. Goldman JM, Apperley J, Jones L, et al.  Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med. 1986;314:202–207
  12. Goldman JM, Gale RP, Horowitz MM, et al.  Bone marrow transplantation for chronic myeloid leukemia in chronic phase. Increased risk of relapse associated with T-cell depletion. Ann Intern Med. 1988;108:806–814
  13. Goldman JM, Szydlo R, Horowitz MM, et al.  Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood. 1993;82:2235–2238
  14. Goldman JM, Druker BJ. Chronic myeloid leukemia: Current treatment options. Blood. 2001;98:2039–2042
  15. Gratwohl A, Gluckman E, Goldman J, et al.  Effect of splenectomy before bone-marrow transplantation on survival in chronic granulocytic leukemia. Lancet. 1985;2:1290–1291
  16. Gratwohl A, Hermans J, Goldman JM, et al.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet. 1998;352:1087–1092
  17. Gratwohl A, van Biezen A, Hermans J, et al.  Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2000;6:211–212
  18. Gratwohl A, Hermans J, Niederwieser D, et al.  Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. Hematol J. 2001;2:363–370
  19. Gratwohl A, Baldomero H, Horisberger B, et al: Current trends in hematopoietic stem cell transplantation in Europe. Blood (in press)
  20. Gratwohl A, Baldomero H, Urbano-Ispizua A. Transplantation in chronic myeloid leukaemia. Lancet. 2002;359:712–713
  21. Gratwohl A, Brand R, Apperley J, et al.  Graft-versus-host disease and outcome in HLA-identical sibling transplants for chronic myeloid leukemia. Blood. 2002;100:3877–3886
  22. Guglielmi C, Arcese W, Hermans J, et al.  Risk assessment in patients with Ph+ CML at first relapse after allogeneic BMT. An EBMT retrospective analysis. Blood. 2000;95:3234–3528
  23. Guglielmi C, Arcese W, Dazzi F, et al.  Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: Prognostic relevance of the initial cell dose. Blood. 2002;100:397–405
  24. Hasford J, Pfirrmann M, Hehlmann R, et al.  A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90:850–858
  25. Hehlmann R, Hochhaus A, Kolb HJ, et al.  Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood. 1999;94:3668–3677
  26. Kantarjian H, Sawyers C, Hochhaus A, et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645–652
  27. Kiss A, Biener D, Grize L, et al.  Psychosocial risk factors for mortality and relapse in the first year after stem-cell transplantation (SCT): A prospective study. Proc EBMT Meeting Montreux, March 24-27, 2002. Bone Marrow Transplant. 2002;29(suppl 2):S51
  28. McSweeney PA, Niederwieser D, Shizuru JA, et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390–4400
  29. Passweg J, Walker I, Sobocinski K, et al.  Validation of the EBMT Risk Score for recipients of allogeneic hematopoetic stem cell transplants for chronic myeloid leukemia (CML). Bone Marrow Transplant. 2002;29(suppl 2):S33
  30. Ruggeri L, Capanni M, Urbani E, et al.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;259:2097–2100
  31. Schmitz N, Beksac M, Hasenclever D, et al.  Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood. 2002;100:761–767
  32. Silver RT, Woolf SH, Hehlmann R, et al.  An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology. Blood. 1999;94:1517–1536
  33. Slattery JT, Clift RA, Buckner CD, et al.  Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89:3055–3060
  34. Slavin S, Nagler A, Shapira MY, et al.  Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation. J Clin Immunol. 2002;22:64–69
  35. Socie G, Clift RA, Blaise D, et al.  Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 2001;98:3569–3576
  36. Sokal JE, Cox EB, Baccarani M, et al.  Prognostic dissemination in “good risk” chronic granulocytic leukemia. Blood. 1984;63:789–799
  37. Speck B, Bortin MM, Champlin R, et al.  Allogeneic bone marrow transplantation for chronic myeloid leukaemia. Lancet. 1984;1:665–668
  38. Stüssi G, Muntwyler J, Passweg JR, et al.  Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;30:87–93
  39. In: ed 2.  Thomas ED,  Blume KG,  Forman SJ editor. Hematopoietic Stem Cell Transplantation. Oxford, UK: Blackwell Science; 1999;
  40. Urbano-Ispizua A, Rozman C, Pimentel P, et al.  The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood. 2001;97:383–387
  41. van Rhee F, Szydlo RM, Hermans J, et al.  Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1997;20:553–560

☆ Address reprint requests to Prof Dr Alois Gratwohl, Division of Hematology, Department of Internal Medicine, Kantonsspital Basel, CH-4031 Basel, Switzerland.

PII: S0037-1963(03)70039-0

Seminars in Hematology
Volume 40, Issue 1 , Pages 13-21 , January 2003

Article Tools

* Image Usage & Resolution